The American Cancer Society (ACS) l...

The American Cancer Society (ACS) lately updated its guideline for the early detection of cervical neoplasia and cancer. The revised guideline was published in the November/December 2002 issue of CA: A Cancer Journal for Clinicians and is also available at CAonline. AmCancer Soc.org/cgi/content/full/52/6/342.

instant Situation

In the past 50 years, mortality from cervical cancer has decreased by way of more than 70 percent, largely because of the Papanicolaou (Pap) trial Preinvasive cervical lesions now are exposeed far more often than invasive malignancies. Because DNA from high-risk representations of sexually transmitted human papillomavirus (HPV) is existing in more than 93 percent of squamous small room cervical cancers, another purpose of screening is to ascertain and remove HPV-associated high-grade lesions before they become cancers.

The ACS notes that the Pap experiment is not perfect and that false-negative deductions cannot be completely eliminated. Various factors, including small lesion size, inaccessible location of the lesion, and failure to sample the lesion, limit standard sensitivity for high-grade cervical intraepithelial neoplasia (CIN) to between 70 and 80 percent

No matter what proof is used, the incidence of cervical cancer can be reduc further by dint of increasing screening rates in women who have at no time been screened or who are guarded infrequently. At present, these women account for approximately 60 percent of cervical cancers diagnosed in the United States.

Initiation of Screening

RECOMMENDATION

The ACS commends that cervical cancer screening begin approximately three years after the storming of vaginal intercourse or no later than 21 years of age. The ACS also emphasizes the importance of providing preventive health care (eg health-risk assessment, prevention counseling, screening for and treatment of sexually transmitted diseases [STDs]) to adolescents who may not ne cervical cytology.

RATIONALE

Data put in mind of that the risk of missing an important cervical lesion is small until three to five years after initial HPV exposing According to the ACS master panel, an upper age limit of 21 years for initiating screening shows a more practical and realistic age than 25 for compliance and access to patients.

The risk of HPV infection and cervical lesions may be increased in victims of sexual abuse who have had vaginal intercourse, particularly after puberty. When these patients are ready to be disguiseed (i.e., after puberty), they should be criterioned by a physician who is experienced in working with abused adolescents.

The patient's choice (after counseling) and the physician's discretion should guide the initiation of cytologic screening in young women 21 years and older who have not had vaginal intercourse and have no history of sexual abuse.

Testing in young women with human immunodeficiency virus (HIV) infection or another condition that compromises the immune scheme (e.g., organ transplantation, chemotherapy, chronic corticosteroid therapy) should be in accordance with U Public Health body guidelines.

Discontinuation of Screening

RECOMMENDATIONS

The ACS praises that women older than 70 years discuss their ne for cervical cancer screening with their physician. Women may elect to discontinue screening after age 70 if they have an intact uterus, three consecutive normal or negative cervical cytologic trials and no abnormal or positive exhibitions within the previous 10 years. Testing may be stopped in women who have censorious comorbid or life-threatening illness.

The ACS commends cervical cytology in women 70 years and older if screening has not been performed previously or is unlikely to have been performed, or information about previous screening is unavailable. Screening should be continued in women who have a history of cervical cancer, a condition that compromises the immune body (e.g., HIV infection), or in utero position to diethylstilbestrol (DES); these women should be guarded for as long as their health is reasonably fit and they have no life-limiting medical condition. Until more information is available, and at the discretion of the physician, screening should continue in women who have exhibitioned positive for HPV DNA.

RATIONALE

The ACS notes that cervical cancer is rare in older covered women in the United States. in the greatest degree cervical cancers in older women come into view in those who have not been covered have not been screened at short intervals or have not had three consecutive normal cytologic tests

Because of atrophy, cervical stenosis, or other conditions, obtaining satisfactory cervical samples from older women may be difficult. Furthermore, screening in this population has potential harms, as it is as discomfort during the transaction and the effects of false-positive consequence s (e.g., invasive procedures, discomfort, increased health care costs) The ACS skilled hand panel set the age to discontinue screening at 70 years in an effort to balance the benefits and harms of screening older women

Screening After Hysterectomy